Alnylam Pharma (ALNY) Misses Q4 EPS by 13c
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Price: $246.67 -1.98%
EPS Growth %: -39.0%
Financial Fact:
Unrealized (loss) gain on marketable securities: -18.33M
Today's EPS Names:
OCCI, ALZN, ASPU, More
EPS Growth %: -39.0%
Financial Fact:
Unrealized (loss) gain on marketable securities: -18.33M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q4 EPS of ($1.69), $0.13 worse than the analyst estimate of ($1.56). Revenue for the quarter came in at $258.5 million versus the consensus estimate of $231.44 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Paychex (PAYX) Tops Q1 EPS by 2c
- H.C. Wainwright Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
- AutoZone (AZO) PT Lowered to $4,230 at UBS Following 'Underwhelming' Q4 Print
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
